DK2640391T3 - Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse - Google Patents
Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse Download PDFInfo
- Publication number
- DK2640391T3 DK2640391T3 DK11841746.8T DK11841746T DK2640391T3 DK 2640391 T3 DK2640391 T3 DK 2640391T3 DK 11841746 T DK11841746 T DK 11841746T DK 2640391 T3 DK2640391 T3 DK 2640391T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- compositions
- treating cognitive
- pyridazine derivatives
- weakness
- Prior art date
Links
- 230000001149 cognitive effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical class C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41397110P | 2010-11-15 | 2010-11-15 | |
| PCT/US2011/060854 WO2012068161A1 (en) | 2010-11-15 | 2011-11-15 | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2640391T3 true DK2640391T3 (da) | 2016-02-15 |
Family
ID=46084380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11841746.8T DK2640391T3 (da) | 2010-11-15 | 2011-11-15 | Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse |
| DK15187794.1T DK3034079T3 (en) | 2010-11-15 | 2011-11-15 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15187794.1T DK3034079T3 (en) | 2010-11-15 | 2011-11-15 | PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9145372B2 (enExample) |
| EP (2) | EP3034079B1 (enExample) |
| JP (1) | JP5916746B2 (enExample) |
| CN (1) | CN103313712B (enExample) |
| AU (1) | AU2011328993B2 (enExample) |
| BR (1) | BR112013012062B1 (enExample) |
| CA (1) | CA2818025A1 (enExample) |
| DK (2) | DK2640391T3 (enExample) |
| EA (1) | EA027840B1 (enExample) |
| MX (2) | MX346185B (enExample) |
| NO (1) | NO3034079T3 (enExample) |
| WO (1) | WO2012068161A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3034079T3 (enExample) | 2010-11-15 | 2018-06-09 | ||
| WO2012071584A2 (en) * | 2010-11-26 | 2012-05-31 | Brigham And Women's Hospital, Inc. | Method for assessing repetitive head injuries with tow-dimensional magnetic resonance spectorscopy |
| CA2885148A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| WO2014078377A1 (en) * | 2012-11-14 | 2014-05-22 | Agenebio, Inc. | Methods and compositions for treating schizophrenia |
| NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| TWI697485B (zh) | 2015-07-21 | 2020-07-01 | 日商捷恩智股份有限公司 | 含唑啉環的化合物、含有其的電子輸送/注入層用材料、使用其的有機電致發光元件、顯示裝置及照明裝置 |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11414425B2 (en) | 2018-06-19 | 2022-08-16 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3941352A1 (en) | 2019-03-19 | 2022-01-26 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| EP0392059B1 (de) | 1989-04-14 | 1993-09-15 | Merz & Co. GmbH & Co. | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie |
| DK0402644T3 (da) | 1989-05-19 | 1996-01-02 | Hoechst Roussel Pharma | N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| EP0478195B1 (en) | 1990-09-21 | 1999-05-26 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones as fungicides |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| JPH07501315A (ja) | 1991-05-24 | 1995-02-09 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 殺節足動物性アニリド |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (enExample) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5763476A (en) | 1994-03-02 | 1998-06-09 | Akzo Noble N.V. | Sublingual or buccal pharmaceutical composition |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| AU1041599A (en) | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| EP1129094A2 (en) | 1998-11-12 | 2001-09-05 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| EP1157989B1 (en) | 1999-03-03 | 2004-09-22 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| CZ20032338A3 (cs) | 2001-03-01 | 2004-08-18 | Pfizeráproductsáinc | Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch |
| WO2003025122A2 (en) | 2001-08-13 | 2003-03-27 | University Of Kentucky Research Foundation | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| AU2003210486B2 (en) | 2002-01-16 | 2007-06-28 | Endo Pharmaceuticals Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| DE60325865D1 (de) * | 2002-08-13 | 2009-03-05 | Merck Sharp & Dohme | Phenylpyridazin derivative als liganden für gaba-rezeptoren |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| EP1556019A2 (en) | 2002-10-24 | 2005-07-27 | Merz Pharma GmbH & Co. KGaA | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| US20040191803A1 (en) | 2002-11-22 | 2004-09-30 | Michela Gallagher | Target for therapy of cognitive impairment |
| WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
| CN101374525A (zh) | 2004-09-23 | 2009-02-25 | 莫茨药物股份两合公司 | 美金刚治疗儿童行为障碍 |
| KR100869388B1 (ko) | 2004-10-12 | 2008-11-21 | 에프. 호프만-라 로슈 아게 | 인지 장애를 치료하기 위한이미다조[1,5-ａ]트라이아졸로[1,5-ｄ]벤조다이아제핀유도체 |
| MX2007004639A (es) | 2004-10-20 | 2007-06-08 | Hoffmann La Roche | Derivados de imidazo-benzodiazepina. |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| AU2006276998A1 (en) | 2005-05-16 | 2007-02-15 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| EP2682481A3 (en) | 2005-08-03 | 2014-09-17 | The Johns-Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010036553A1 (en) * | 2008-09-24 | 2010-04-01 | E. I. Du Pont De Nemours And Company | Fungicidal pyridazines |
| CN102223790B (zh) | 2008-09-25 | 2015-11-25 | 维乌作物保护有限公司 | 生产聚合物纳米颗粒的方法和活性成分的制剂 |
| US8344028B2 (en) | 2009-04-17 | 2013-01-01 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as GABAB receptor ligands |
| WO2011085406A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| NO3034079T3 (enExample) * | 2010-11-15 | 2018-06-09 | ||
| AU2011329068A1 (en) | 2010-11-15 | 2013-06-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment |
| JPWO2012161133A1 (ja) * | 2011-05-20 | 2014-07-31 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| EP2892521A4 (en) | 2012-09-10 | 2016-06-29 | Ophirex Inc | ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS FOR THE ALLOCATION OF NEUROTOXININDUCED FLUCTUATIONS AND THE REMAINING NEUROMUSCULAR BLOCKADES |
| NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2011
- 2011-11-15 NO NO15187794A patent/NO3034079T3/no unknown
- 2011-11-15 AU AU2011328993A patent/AU2011328993B2/en not_active Ceased
- 2011-11-15 DK DK11841746.8T patent/DK2640391T3/da active
- 2011-11-15 EA EA201390712A patent/EA027840B1/ru not_active IP Right Cessation
- 2011-11-15 US US13/885,569 patent/US9145372B2/en not_active Expired - Fee Related
- 2011-11-15 BR BR112013012062-2A patent/BR112013012062B1/pt not_active IP Right Cessation
- 2011-11-15 MX MX2013005442A patent/MX346185B/es active IP Right Grant
- 2011-11-15 EP EP15187794.1A patent/EP3034079B1/en active Active
- 2011-11-15 MX MX2017003111A patent/MX383953B/es unknown
- 2011-11-15 JP JP2013539003A patent/JP5916746B2/ja active Active
- 2011-11-15 EP EP11841746.8A patent/EP2640391B1/en active Active
- 2011-11-15 CA CA2818025A patent/CA2818025A1/en not_active Abandoned
- 2011-11-15 CN CN201180063261.2A patent/CN103313712B/zh not_active Expired - Fee Related
- 2011-11-15 WO PCT/US2011/060854 patent/WO2012068161A1/en not_active Ceased
- 2011-11-15 DK DK15187794.1T patent/DK3034079T3/en active
-
2015
- 2015-09-18 US US14/858,959 patent/US9801879B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013012062A2 (pt) | 2016-08-16 |
| US9801879B2 (en) | 2017-10-31 |
| JP2013542267A (ja) | 2013-11-21 |
| EA201390712A1 (ru) | 2013-11-29 |
| CN103313712A (zh) | 2013-09-18 |
| EA027840B1 (ru) | 2017-09-29 |
| CA2818025A1 (en) | 2012-05-24 |
| MX383953B (es) | 2025-03-14 |
| JP5916746B2 (ja) | 2016-05-11 |
| WO2012068161A1 (en) | 2012-05-24 |
| EP2640391A4 (en) | 2014-05-07 |
| US9145372B2 (en) | 2015-09-29 |
| EP2640391A1 (en) | 2013-09-25 |
| AU2011328993A1 (en) | 2013-06-06 |
| EP3034079B1 (en) | 2018-01-10 |
| CN103313712B (zh) | 2016-10-26 |
| US20160008357A1 (en) | 2016-01-14 |
| MX2013005442A (es) | 2013-10-03 |
| NO3034079T3 (enExample) | 2018-06-09 |
| DK3034079T3 (en) | 2018-02-05 |
| AU2011328993B2 (en) | 2017-03-02 |
| EP3034079A1 (en) | 2016-06-22 |
| US20130237545A1 (en) | 2013-09-12 |
| MX346185B (es) | 2017-03-10 |
| EP2640391B1 (en) | 2015-11-11 |
| BR112013012062B1 (pt) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2640391T3 (da) | Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse | |
| DK3202460T3 (da) | Arylmethoxy-isoindolinderivater og sammensætninger omfattende og fremgangsmåder til anvendelser af samme | |
| DK2247582T3 (da) | Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf | |
| DK2585437T3 (da) | Thioacetatforbindelser, sammensætninger og fremgangsmåder til anvendelse heraf | |
| DK3064585T3 (da) | Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation | |
| DK3569256T3 (da) | Stabiliserede fibronectin-domænesammensætninger, fremgangsmåder og anvendelser | |
| DK2688557T3 (da) | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed | |
| DK2699553T3 (da) | Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK4289948T3 (da) | Fremgangsmåder og sammensætninger til rna-dirigeret mål-dna-modificering og til rna-dirigeret modulering af transkription | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
| DK3127540T3 (da) | Visse amino-pyrimidiner, sammensætninger deraf, og fremgangsmåder til deres anvendelse | |
| DK2890780T3 (da) | Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand | |
| DK3795573T3 (da) | Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf | |
| DK3329775T3 (da) | Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser | |
| DK2987507T3 (da) | Fremgangsmåder til behandling af degenerative knogletilstande | |
| DK2489670T3 (da) | Fremgangsmåde til fremstilling af aminosyre-chelatforbindelser, aminosyre-chelatforbindelser og anvendelse af aminosyre-chelatforbindelser | |
| DK2598500T3 (da) | Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen | |
| DK3260118T3 (da) | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion | |
| DK3443957T3 (da) | Forbindelser og sammensætninger til behandling af cancer | |
| DK2446246T3 (da) | Indretning og fremgangsmåde til udvælgelse af partikler | |
| DK2830654T3 (da) | Metoder og sammensætninger til behandling af inflammation | |
| DK3284820T3 (da) | Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger | |
| DK2415349T3 (da) | Fremgangsmåde til fremstilling af afsaltet mælk, og afsaltet mælk |